Higher mutational load correlated positively with immunogenicity and thus T cell infiltration and was a predictor for clinical response to anti-PD-1 inhibition in non-small cell lung cancer (NSCLC) [15]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.